Squarepoint Ops LLC acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,758 shares of the biopharmaceutical company's stock, valued at approximately $130,000. Squarepoint Ops LLC owned 0.08% of Nektar Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of NKTR. SG Americas Securities LLC increased its holdings in shares of Nektar Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 11,681 shares during the period. Moloney Securities Asset Management LLC increased its holdings in shares of Nektar Therapeutics by 42.4% in the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 14,895 shares during the period. Peapod Lane Capital LLC acquired a new position in shares of Nektar Therapeutics in the fourth quarter valued at about $1,030,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Nektar Therapeutics by 12.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company's stock worth $680,000 after buying an additional 80,034 shares during the last quarter. Finally, Monaco Asset Management SAM boosted its stake in shares of Nektar Therapeutics by 1.8% in the fourth quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 35,648 shares during the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have recently commented on NKTR. Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. HC Wainwright restated a "buy" rating and issued a $97.50 target price on shares of Nektar Therapeutics in a research note on Thursday, March 13th. Oppenheimer upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price on the stock in a research note on Friday, March 14th. Finally, William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $67.50.
Check Out Our Latest Stock Analysis on Nektar Therapeutics
Nektar Therapeutics Price Performance
NKTR stock traded down $0.17 during mid-day trading on Friday, reaching $8.59. 441,266 shares of the company's stock were exchanged, compared to its average volume of 135,644. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -10.23 and a beta of 0.55. The stock's 50 day moving average is $9.97 and its 200 day moving average is $12.26. Nektar Therapeutics has a 12-month low of $6.48 and a 12-month high of $22.79.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million for the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. During the same quarter in the prior year, the company posted ($2.70) EPS. On average, research analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.
Nektar Therapeutics Profile
(
Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
